How far along are we in revealing the connection between metformin and colorectal cancer?
Open Access
- 14 April 2021
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 27 (14), 1362-1368
- https://doi.org/10.3748/wjg.v27.i14.1362
Abstract
Colorectal cancer (CRC) is among the most prevalent cancers worldwide, and its prevention and reduction of incidence is imperative. The presence of diabetes has been associated with a 30% increased risk of CRC, likely through the mechanism of hyperinsulinemia, which promotes tumorigenesis via the insulin receptor in the epithelium or by insulin-like growth factor pathways, inflammation, or adipokines, inducing cancer cell proliferation and cancer spread. Metformin, the first-line agent in treating type 2 diabetes, has a chemopreventive role in CRC development. Additionally, preclinical studies suggest synergistic effects of metformin with oxaliplatin in inhibiting in vitro models of colon cancer. Although preclinical studies on the post diagnostic use of metformin were promising and suggested its synergistic effects with chemotherapy, the data on the possible effects of metformin after surgery and other CRC treatment in the clinical setting are less conclusive, and randomized controlled trials are still lacking.Keywords
This publication has 51 references indexed in Scilit:
- Activation of AMP-Activated Protein Kinase and Extracelluar Signal-Regulated Kinase Mediates CB-PIC-Induced Apoptosis in Hypoxic SW620 Colorectal Cancer CellsEvidence-Based Complementary and Alternative Medicine, 2013
- Metformin and the Risk of CancerDiabetes Care, 2012
- Metformin efficacy and safety for colorectal polyps: a double-blind randomized controlled trialBMC Cancer, 2012
- microRNA-21-mediated regulation of Sprouty2 protein expression enhances the cytotoxic effect of 5-fluorouracil and metformin in colon cancer cellsInternational Journal of Molecular Medicine, 2012
- Metformin Suppresses Colorectal Aberrant Crypt Foci in a Short-term Clinical TrialCancer Prevention Research, 2010
- Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk: mTOR , PTEN , STK11 , RPKAA1 , PRKAG2 , TSC1 , TSC2 , PI3K and Akt1Carcinogenesis: Integrative Cancer Research, 2010
- Insulin resistance and hyperinsulinaemia in the development and progression of cancerClinical Science, 2009
- Convergence of Hormones, Inflammation, and Energy-Related Factors: A Novel Pathway of Cancer EtiologyCancer Prevention Research, 2009
- The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein KinaseCancer Prevention Research, 2008
- Diabetes Mellitus and Risk of Colorectal Cancer: A Meta-AnalysisJNCI Journal of the National Cancer Institute, 2005